Clinical Trial · NCT07733908

Effectiveness of Posluma PET Scan for Post-Treatment Monitoring of Prostate Cancer

Overview

To determine the effectiveness of Posluma PET Scan for monitoring prostate cancer patients after targeted treatment, including how accurately it can detect any remaining or returning cancer after about 12 months post-treatment.

Sponsor

University of California, San Francisco

Phase

Phase 2

Contacts

Translational Research Team (CONTACT)

cancercto@health.ucsd.edu

(858) 822-5354

Aditya Bagrodia, MD, FACS (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT07733908

Drug / Compound

flotufolastat

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Eligibility

Inclusion

Eligibility for Focal Therapy: Determined to be an appropriate candidate for focal therapy based on clinical evaluation.
Risk Profile: Intermediate-risk , organ-confined PCa
Diagnosis: Histologically confirmed PCa.

Exclusion

Previous Treatment: Prior treatment for PCa, including radiation therapy, chemotherapy, focal therapy, or androgen deprivation therapy.